自发性细菌性腹膜炎预防与治疗进展

doi:10.3969/j.issn.1672-5069.2014.04.004

摘要/Abstract

Key words: Spontaneous bacterial peritonitis, Liver cirrhosis, Empirical/Preventive medicine, Advance

黄利华, 张英. 自发性细菌性腹膜炎预防与治疗进展[J]. 实用肝脏病杂志, 2014, 17(4): 348-352.

Huang Lihua, Zhang Ying. Prevention and treatment of spontaneous bacterial peritonitis: what is new?[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(4): 348-352.

[1] Gines P,Angeli P,Lenz K,et al.EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53（3）:397- 417.
[2] Burri E,Schulte F,Muser J,et al. Measurement of calprotectin in ascitic fluid to identify elevated polymorphonuclear cell count. World J Gastroenterol,2013,19（13）:2028-2036.
[3] Lippi G,Danese E,Cervellin G,et al. Laboratory diagnostics of spontaneous bacterial peritonitis. Clin Chim Acta,2014,20:164-170.
[4] Mostafa MS,El-Seidi EA,Kassem AM,et al. Detection of ascitic fluid infections in patients with liver cirrhosis and ascites. Arab J Gastroenterol,2011,12（1）:20-24.
[5] Cho Y,Park SY,Lee JH,et al. High-sensitivity C-reactive protein level is an independent predictor of poor prognosis in cirrhotic patients with spontaneous bacterial peritonitis. J Clin Gastroenterol,2014,48（5）:444-449.
[6] Shalimar1 H,Acharya SK. Difficult to treat spontaneous bacterial peritonitis. Trop Gastroenterol,2013,34（1）:7-13.
[7] Alexopoulou A,Papadopoulos N,Eliopoulos DG,et al. Increasing frequency of gram-positive cocci and gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis. Liver Int,2013,33（7）:975-981.
[8] 卜昕,张文瑾,范振平,等.肝硬化并发自发性细菌性腹膜炎患者腹水感染161 例的细菌种类及耐药分析.中华临床医师杂志, 2012,6（13）:3734-3737.
[9] 涂清鲜,袁萍萍.病毒性重症肝炎并发自发性腹膜炎病原菌分析.吉林医学,2011,32（3）:556.
[10] Bhat G,Vandana KE,Bhatia S,et al. Spontaneous ascitic fluid infection in liver cirrhosis:bacteriological profile and response to antibiotic therapy.Indian J Gastroenterol,2013,32（5）:297-301.
[11] 姚光弼. 临床肝脏病学. 上海：上海科学技术出版社,2011,181-186.
[12] Acevedo JL,Prado V,Fernández J,et al. Changing options for prevention and treatment of infections in cirrhosis. Curr Treat Options Gastroenterol,2014,12（2）:256-267.
[13] Badawy AA,Zaher T,Sharaf SM,et al. Effect of alternative antibiotics in treatment of cefotaxime resistant spontaneous bacterial peritonitis. World J Gastroenterol,2013,19（8）:1271-1277.
[14] Yakar T,Güclü M,Serin E,et a1.A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci,2010,55（4）：1149-1154.
[15] Guevara M,Terra C,Nazar A,et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis.A randomized,controlled study. J Hepatol,2012,57（4）:759-765.
[16] Narula N,Tsoi K,Marshall JK. Should albumin be used in all patients with spontaneousbacterial peritonitis Can J Gastroenterol,2011,25（7）:373-376.
[17] Garcia-Martinez R,Caraceni P,Bernardi M,et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology,2013,58（5）:1836-1846.
[18] Rena NM,Wibawa ID.Albumin infusion in liver cirrhotic patients. Acta Med Indones,2010,42（3）：162-168.
[19] Deshpande A,Pasupuleti V,Thota P,et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients:a meta-analysis.J Gastroenterol Hepatol,2013,28（2）:235-242.
[20] Kwon JH,Koh SJ,Kim W,et al. Mortality associated with proton pump inhibitors in cirrhotic patients with spontaneous bacterial peritonitis. J Gastroenterol Hepatol,2014,29（4）:775-781.
[21] 郑三菊,王崇慧,占国清.微生态制剂治疗肝硬化自发性细菌性腹膜炎疗效观察. 中国微生态学杂志,2014,26（1）:62-65.
[22] Cesaro C,Tiso A,Del Prete A,et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis,2011,43（6）:431-438.
[23] Pereg D,Kotliroff A,Gadoth N,et al.Probiotics for patients with compensated liver cirrhosis:a double-blind placebo-controlled study. Nutrition,2011,27（2）:177-181.
[24] Saab S,Hernandez JC,Chi AC,et al.Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol,2009,104（4）:993-1001.
[25] Lontos S,Shelton E,Angus PW,et al. A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients. J Dig Dis,2014,15（5）:260-267.
[26] Lee YY,Tee HP,Mahadeva S. Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding. World J Gastroenterol,2014,20（7）:1790-1796.

自发性细菌性腹膜炎预防与治疗进展

Prevention and treatment of spontaneous bacterial peritonitis: what is new?

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[3]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[4]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[5]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[6]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[7]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[8]	杨东亮, 刘嘉, 吴珺, 郑昕. 肝脏免疫学研究若干进展与挑战[J]. 实用肝脏病杂志, 2019, 22(5): 609-612.
[9]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[10]	王月圆, 王燕, 张丹丹. 奥曲肽辅助特利加压素治疗失代偿期肝硬化并发肝肾综合征患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(5): 684-687.
[11]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[12]	丹珠永吉, 刘芝兰, 禄艳艳, 蒋汉梅. 内镜下序贯套扎和硬化剂治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效及对血流动力学的影响对比研究*[J]. 实用肝脏病杂志, 2019, 22(5): 692-695.
[13]	黄汉军, 鲁凤荣, 张灿. 基于Exchange血流动力学模型的MRI扫描参数诊断肝硬化临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(5): 696-699.
[14]	赵芳芳, 翟永贞, 冯国和. 自体外周血干细胞移植治疗乙型肝炎肝硬化患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(5): 700-703.
[15]	陈山, 庄华帅, 邢诒喜, 吴直佳. 美罗培南治疗肝硬化并发上消化道出血患者对感染预防和再出血的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 704-707.